MedTrace Logo

Toclizumam Versus Dexamethasone in Severe Covid-19 Cases

NCT04519385 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2020-08-25

No results posted yet for this study

Summary

randomized controlled trial comparing survival benefit of Tocilizumab therapy with dexamethasone in patients with severe COVID 19

Conditions

  • Pneumonia, Viral

Interventions

DRUG

Tocilizumab

Tocilizumab therapy

DRUG

Dexamethasone

dexamethsone pulse therapy

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Alaa R rashad, MD · South Valley University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-07-01
Completion
2020-08-05

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04519385 on ClinicalTrials.gov